Core Viewpoint - The company, Jiangsu Haobio Pharmaceutical Co., Ltd., is experiencing a decline in revenue and net profit, while its stock is trading at a significantly high price-to-earnings (PE) ratio compared to the industry average. Group 1: Company Performance - As of the latest report, the company achieved a revenue of 77.61 million yuan in Q1 2025, representing a year-on-year decrease of 9.33% [2] - The net profit for the same period was 1.64 million yuan, down 56.97% year-on-year, with a gross profit margin of 57.98% [2] - The company's stock closed at 116.9 yuan, with a PE ratio of 214.27, significantly higher than the industry average of 57.48 [1][3] Group 2: Industry Comparison - The average PE ratio for the medical device industry is 57.48, with a median of 40.95, placing Haobio at the 115th position among its peers [1][3] - The company holds 12 institutional investors, all of which are funds, with a total holding of 1.1392 million shares valued at 15.5 million yuan [1]

Company Overview - Jiangsu Haobio Pharmaceutical Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents, with key products including allergy reagents and autoimmune reagents [2] - The company has obtained 226 product registration certificates and holds 57 patents, recognized as a high-tech enterprise [2] Financial Performance - For Q1 2025, the company reported revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97% [2] - The gross profit margin stands at 57.98% [2] Market Position - As of August 5, the company's stock closed at 118.7 yuan, with a rolling PE ratio of 217.57 times, significantly higher than the industry average of 54.24 times and the median of 37.92 times [1][3] - The total market capitalization is 7.535 billion yuan [1] Institutional Holdings - By the end of Q1 2025, 12 institutions held shares in Haobio, with a total of 1.1392 million shares valued at 155 million yuan [1]

Company Overview - Jiangsu Haobio Pharmaceutical Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents, with key products including allergy and autoimmune reagents [2] - The company holds 226 product registration certificates and 57 patents, and is recognized as a high-tech enterprise with multiple awards and honors [2] Financial Performance - For Q1 2025, the company reported revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97% [2] - The gross profit margin for the same period was 57.98% [2] Market Position - As of July 30, the company's stock closed at 120.91 yuan, down 3.13%, with a rolling price-to-earnings (PE) ratio of 221.62, significantly higher than the industry average of 55.15 [1][3] - The total market capitalization of the company is 7.675 billion yuan [1] Institutional Holdings - By the end of Q1 2025, 12 institutions held shares in the company, all of which were funds, with a total holding of 1.1392 million shares valued at 15.5 million yuan [1]

Core Viewpoint - Jiangsu Haobio's stock closed at 124.82 yuan, with a PE ratio of 228.78 times, significantly higher than the industry average of 55.46 times, indicating potential overvaluation in the market [1][3] Company Overview - Jiangsu Haobio specializes in the research, production, and sales of in vitro diagnostic reagents, with key products including allergy and autoimmune reagents [2] - The company holds 226 product registration certificates and 57 patents, and has received multiple honors, including being recognized as a high-tech enterprise and a "national specialized and innovative 'little giant' enterprise" [2] Financial Performance - For Q1 2025, the company reported revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97% from the previous year, with a gross margin of 57.98% [2] Market Position - The company's market capitalization stands at 7.924 billion yuan, ranking 114th in the medical device industry based on PE ratio, which is significantly higher than the industry median of 37.74 times [1][3]

Group 1 - The core business of the company is the research, production, and sales of in vitro diagnostic reagents, with major products including allergy reagents and autoimmune reagents [2] - As of the latest report, the company has obtained 226 product registration certificates and holds 57 patents, indicating a strong position in innovation and technology [2] - The company has received multiple honors, including being recognized as a high-tech enterprise and receiving various awards for innovation and creditworthiness [2] Group 2 - As of June 3, the company's stock closed at 93.24 yuan, down 2.70%, with a rolling PE ratio of 169.77 times, significantly higher than the industry average of 50.80 times [1][3] - The total market capitalization of the company is 5.88 billion yuan, ranking 113th in the industry based on PE ratio [1][3] - The latest quarterly report for Q1 2025 shows a revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97% year-on-year, with a gross margin of 57.98% [2]

Company Overview - Jiangsu Haooubo Biomedicine Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents, with key products including allergy reagents and autoimmune reagents [2] - The company holds 226 product registration certificates and 57 patents, and is recognized as a high-tech enterprise with multiple awards for innovation and creditworthiness [2] Financial Performance - For Q1 2025, the company reported revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97% year-on-year, with a gross margin of 57.98% [2] Market Position - As of May 29, the company's stock closed at 89.1 yuan, with a rolling price-to-earnings (PE) ratio of 162.23, significantly higher than the industry average PE of 49.64 and median PE of 36.36, placing the company at rank 114 in the industry [1][3] - The total market capitalization of the company is 5.618 billion yuan [1] Shareholder Information - As of March 31, 2025, the company had 3,065 shareholders, an increase of 30 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

Core Viewpoint - Jiangsu Haobio's stock closed at 86.8 yuan, down 4.67%, with a rolling PE ratio of 158.04 times, significantly higher than the industry average of 49.84 times [1][3] Company Overview - Jiangsu Haobio Biopharmaceutical Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents, with key products including allergy and autoimmune reagents [2] - The company holds 226 product registration certificates and 57 patents, recognized as a high-tech enterprise and awarded multiple honors, including "Innovative Pioneer Enterprise" and "National Specialized and New 'Little Giant' Enterprise" [2] Financial Performance - For Q1 2025, the company reported revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97%, with a gross margin of 57.98% [2] Market Position - As of Q1 2025, 11 institutions held shares in Haobio, with a total of 46.12 million shares valued at 4.007 billion yuan [1]